Introduction
MicroRNAs (miRNAs) are a class of naturally occurring small non-coding RNAs that control gene expression by targeting mRNAs for translational repression or cleavage (Bartel, 2004) . miRNAs are transcribed as long primary transcripts in the nucleus and are subsequently cleaved to produce stem-loop structured precursor molecules of B70 nt length (pre-miRNAs) by Drosha, which are then exported to the cytoplasm, where the RNase III enzyme Dicer further processes them into an B22-nucleotide miRNA. Consequently, translation blockade or mRNA degradation will occur depending on whether it is partially matched or perfectly matched with target genes, respectively (Ambros, 2004; Murchison and Hannon, 2004) . The functional miRNAs have been predicted to control up to 20-30% genes within the human genome (Lewis et al., 2005) .
Aberrant expression of miRNAs in cancer has been well documented (Calin et al., 2004a, b; Iorio et al., 2005) . Apparently, miRNAs may function as tumor suppressors or oncogenes by targeting oncogenes or tumor suppressor genes. It was reported that the identification of a mechanism of regulation of BCL2 expression in hematopoietic cancer cells consisted of post-transcriptional downregulation by miR-15 and miR-16 (Cimmino et al., 2005) . In human ovarian cancer, aberrantly expressed miR-214 can negatively regulate PTEN by binding to its 3 0 -UTR leading to the inhibition of PTEN translation and activation of the Akt pathway (Yang et al., 2008) . Expression of miR-21 was remarkably elevated in human glioblastoma and contributed to the malignant phenotype by blocking the expression of critical apoptosis-related genes (Chan et al., 2005) . Furthermore, miR-21 was reported to induce invasion/intravasation/metastasis in colorectal cancer (Asangani et al., 2007) . miR-373 expression has been correlated with increased invasion and metastasis in breast cancer (Huang et al., 2008) . miR-10b is highly expressed in metastatic breast cancer cells and positively regulates breast cancer invasion (Ma et al., 2007) . Expression of miR-126 and miR-335 is lost in the majority of primary breast tumors from patients who relapse, and the loss of expression of either miRNA is associated with poor distal metastasis-free survival (Tavazoie et al., 2008) . However, although miRNAs have been the subject of extensive research in recent years, the molecular mechanisms of miRNA-mediated gene regulation and the effects on tumors remain largely unknown because of our limited understanding of miRNA targets.
The urokinase-type plasminogen activator (uPA) is a kind of serine protease. uPA catalyses the conversion of the inactive zymogen plasminogen into the active broadspectrum plasmin, which degrades a number of matrix proteins and also activates other proteases, including some matrix metalloproteinases (Rabbani and Xing, 1998; Sidenius and Blasi, 2003) . In the past, uPAs have been shown to have a major role in regulating cancer cells motility, extracellular matrix invasion and metastasis by degrading the extracellular matrix proteins (Blasi, 1993; Busso et al., 1994; Chapman, 1997) . High levels of uPA produced by tumor cells and the stroma surrounding the tumor are involved in the process of invasion, metastasis and angiogenesis of several malignancies, including breast cancer (Tetu et al., 1998; Teˆtu et al., 2001) . Overexpression of uPA is directly associated with tumor growth, invasion and metastasis (Achbarou et al., 1994; Sliva et al., 2002; Pakneshan et al., 2004a, b; Pulukuri and Rao, 2007) . Our experiments identify that uPA is a target of miR-193b. miR193b may function as a suppressor in the process of breast cancer pathogenesis and progression by targeting uPA expression.
Results

miR-193b is downregulated during metastasis in a mouse xenograft model
We performed microRNA array profiling of MDA-MB-231 human breast cancer cell derivatives that are highly metastatic to the lung, MDA-MB-231-HM, as well as the parental, unselected MDA-MB-231 cell line. Of the 435 human microRNAs assayed, 88 microRNAs were found to be differentially expressed in replicate experiments (Supplementary Table 1 ). When the false-discovery rate was set to o5%, only 10 genes were found to be significantly upregulated, whereas nine were determined to be significantly downregulated.
To identify directly metastasis-associated miRNAs, our approach was to seek evidence of miRNAs in the regulation of pathways and targets that are logical candidates based on our current knowledge about metastasis. The metastatic program encompasses multiple sequential steps: cell motility, tissue invasion, intravasation, dissemination through the blood or lymph, extravasation and finally proliferation at a new site (Gupta and Massague´, 2006) . A large set of candidate genes underlying each step hasbeen identified (Johnsen et al., 1998; McSherry et al., 2007; Rabbani and Mazar, 2007) . In our research, we attempted to connect these metastasis regulators with the 19 selected miRNAs in the array profiling. TargetScan, PicTar and miRanda were used for our initial prediction (Lewis et al., 2003; John et al., 2004; Krek et al., 2005) . miR193b and uPA were of particular interest, as we noticed a binding site for hsa-miR-193b in the uPA 3 0 -UTR ( Figure 1a) .
uPA was a key regulator of breast cancer invasion and metastasis (Sidenius and Blasi, 2003) . The expression levels of uPA in several human breast cancer cell lines were correlated with their in vitro invasiveness (Holst- Hansen et al., 1996) , and the induction of uPA overexpression was directly associated with the highly invasive characteristics of breast cancer (Pakneshan et al., 2004a, b) . We confirmed that MDA-MB-231-HM cells expressed lower miR-193b compared with MDA-MB-231 by real-time PCR (Figure 1b) . We also tested between MDA-MB-231 and MDA-MB-231-HM cell lines the uPA mRNA expression levels and uPA protein expression levels, and it was amazing to find that compared with MDA-MB-231, the uPA protein abundance was greatly increased in MDA-MB-231-HM with the uPA mRNA levels almost unchanged (Figures 1c-e) . As most miRNAs are thought to function by inhibiting the translation of their mRNA targets (Ambros, 2004) , in view of the above observations, a hypothetical model suggesting an interplay between miR-193b and uPA was proposed: miR-193b might be a negative regulator for uPA. During breast cancer cell metastasis, the expression of miR-193b is downregulated, which in turn contributes to enhanced uPA expression and invasion. Across the five cell lines tested we observed a significant inverse correlation between miR-193b and uPA protein levels (P ¼ 0.037; Spearman's correlation, r ¼ À0.9).
The 3
0 UTR of uPA mRNA is a direct target of miR-193b To confirm whether miR-193b directly targets the 3 0 UTR of uPA, the 3 0 UTR region of the uPA gene was cloned downstream of the luciferase open reading frame (ORF) to construct a reporter plasmid 3 0 UTRuPA-luc (Figure 3a) . Transient transfection of T47D cells, with a high endogenous miR-193b level, with the wild-type 3 0 UTR-uPA-luc reporter and anti-193b inhibitor, led to a significant increase in reporter activity compared with control oligo (Figure 3b ). Overexpression of miR-193b in MDA-MB-231 cells elicited a significant decrease of the luciferase activity of 3 0 UTRuPA-luc (Figure 3c ). The same observation was made with MDA-MB-435 cells (Figure 3d ). However, miR193b could no longer decrease the luciferase activity of a mutant construct-with substitutions of four nucleotides in the miR-193b-binding site (Figure 3d ). These results supported the bioinformatic prediction that the 3 0 UTR of uPA mRNA might be a direct target for miR193b, and denoted that the matching site identified strongly contributed to the miRNA-mRNA interaction mediating the inhibition of uPA expression. Taken together, we propose from these assays that miR-193b remarkably decreases uPA expression by inhibiting the translation process, but does not target the uPA mRNA for degradation.
In the Matrigel invasion and transwell migration assays, miR-193b-transfected clones MDA-MB-231/ 193b and MDA-MB-435/193b had significantly lower invasion and migration potential when compared with mock-transfected or wild-type cells (Figure 6a ). In both cell lines, ectopic expression of miR-193b had an inhibitory effect on their proliferation in vitro (Figure 6b ). We next ascertained whether reduced uPA levels might be an explanation for the decreased cell invasiveness and motility observed following miR-193b expression. A construct expressing human uPA was transfected into MDA-MB-231/193b cells. This construct encodes the entire uPA-coding region, but lacks the 3 0 UTR of uPA, yielding an mRNA that is resistant to miR-193b-mediated inhibition of translation. Strikingly, exogenous uPA expression nearly completely restored the migratory or invasive phenotype in cells overexpressing miR-193b (Figure 6c ). The resulting constitutive expression of uPA also restored miR193b-induced inhibition on cell proliferation (data not shown). These data indicate that the overexpression of miR-193b is sufficient to inhibit invasion, migration and proliferation. These findings suggest that uPA is indeed a functionally important target of miR-193b, and that uPA downregulation is necessary for miR-193b-mediated repression of proliferation, migration and invasion.
Ectopic expression of miR-193b inhibits orthotopic tumor growth and spontaneous pulmonary metastasis in SCID mice Mice injected with MDA-MB-231/193b cells developed mammary tumors of significantly smaller volume compared with mice inoculated with mock-transfected or wild-type cells (Figures 7a and b , Po0.01). When studying the pulmonary metastasis, it was clear that there was a 50% decrease in lung metastasis in the miR193b group compared with that in the mock-transfected or wild-type group (Figures 7c and d, Po0.01 ). To 0 UTR-uPA-luc construct, whereas no change in the luciferase activity of mutant 3 0 UTR-uPA-luc construct was seen. *P-value o0.05.
MiR-193b regulates the expression of uPA in breast cancer X-F Li et al illuminate the changes in the xenografts, we detected the expression of uPA protein by immunohistochemistry, and we verified that decreased uPA protein expression existed in the miR-193b-transfected cell xenografts compared with the control xenografts ( Figure 7d ). However, we were unable to detect a negative regulation of metastasis and growth of xenograft tumors developed from MDA-MB-435 cells. As uPA is expressed at a very low level in MDA-MB-435 cells (Holst-Hansen et al., 1996) , the knockdown of uPA by miR-193b might be insufficient to reduce the metastatic and proliferative capacity of MDA-MB-435 cells in vivo.
It would be interesting to see whether reduced uPA was also predominantly responsible for the decrease in tumor growth and metastasis in vivo. We addressed this concern by comparing the MDA-MB-231/193b/uPA overexpressing cell line and the MDA-MB-231/193b cell line in the xenograft experiments. The assays were performed using the methods described above. MDA-MB-231/193b/uPA cells grew faster and developed more lung metastasis than MDA-MB-231/193b cells in nude mice (Figures 7e-h ). These data further support the notion that suppression of uPA is required for the inhibition of growth and invasion of MDA-MB-231 cells mediated by the stable expression of miR-193b in vivo. Immunohistochemical staining verified lower expression of uPA in the MDA-MB-231/193b xenografted tumors than in the MDA-MB-231/193b/uPA xenografted tumors (data not shown).
miR-193b expression in clinical metastasis
To determine whether the miRNA is associated with human metastasis, we examined the relative expression of miR-193b in a collection (non-matched) of 40 lymph node-positive and 40 lymph node-negative human primary breast tumors by real-time PCR. The relationship between the relative miR-193b expression and patients' clinical characteristics is shown in Supplementary Table 2 . As can be seen, no significant association was found between the miR-193b level and ER, PR or Her-2 status in cancer tissues. However, miR-193b expression was related to tumor stage and tumor grade. We found that the mean expression of miR-193b in patients with metastasis to lymph node was notably lower that the mean expression in patients without metastasis using a two-tailed Mann-Whitney U-test (Figure 8a) . Interestingly, these results are in conso- (Figure 2a ). Significantly, patients with low miR-193b expression had a higher percentage of lymph node metastasis (Figure 8b ). We further investigated the expression of uPA mRNA by real-time PCR; however, we did not detect a significant difference between these 40 lymph nodepositive and 40 lymph node-negative human primary breast tumors (Figure 8c ). The mean expression of uPA antigen was significantly higher in the group of patients with lymph node metastasis compared with those without lymph node metastasis (data not shown); Spearman's correlation analysis showed a significant positive relationship between the likelihood of lymph node metastasis and uPA antigen expression in these tumors (Figure 8d ). More importantly, there was a statistically significant Spearman's correlation that characterized an inverse relationship between the miR193b expression level and the uPA protein level (Figure 8e) . In contrast to the protein level, no strong correlation was observed between the miR-193b level and the uPA mRNA level (data not shown). These in vivo data suggested that miR-193b is a negative regulator for uPA at the post-transcriptional level. The decreased expression of miR-193b would be one of the causes of high expression of uPA in breast cancerous tissues.
The expression of miR-193b also correlates with the metastasis-free survival of breast cancer patients. When comparing the overall survivals, we showed that high miR-193b expression is positively correlated with the disease-free survival of all patients, especially in patients with lymph node metastasis ( Supplementary Figure 1 , P-value o0.01).
Discussion
In recent years, a series of studies have shown that the expression of miRNAs is deregulated in human malignancies (Calin et al., 2004a, b; Iorio et al., 2005) . Identification of cancer-specific miRNAs and their targets is critical for understanding their role in tumorigenesis and may be important for defining novel therapeutic targets (Chan et al., 2005; Cimmino et al., 2005) .
The 3 0 UTR of uPA has been shown to have a vital role in the post-transcriptional control of uPA expression (Nanbu et al., 1994) . During Nanbu's research, three independent determinants of instability were found to locate in the 3 0 UTR of uPA mRNA: one was the AU-rich sequence located immediately 3 0 of the poly(A) addition signal, and the others were two separate sequences residing upstream of the AU-rich region. In addition, they reported a fourth region 'C' that showed no effect on the stability of uPA mRNA. By coincidence, the binding site on the 3 0 UTR of uPA for miR-193b to inhibit the translation of uPA mRNA in our report was within region'C'. Therefore, we supplemented here Nanbu's research and characterized a novel regulatory element on the 3 0 UTR of uPA. This is the first study to show that the tumor invasion inducer uPA is negatively regulated by miR-193b at the posttranscriptional level. It is also the first study to show that miR-193b curbs the invasion/metastasis of breast cancer cells. Downregulation of miR-193b in MDA-MB-231 cells upregulated uPA expression and strengthened cell invasiveness. Overexpression of miR-193b in MDA-MB-231 and MDA-MB-435 cells inhibited uPA expression and cell invasion. Xenograft tumor experiments provided additional support for the involvement of miR-193b in regulating breast cancer cell growth and metastasis. miR-193b could strikingly inhibit the growth and invasion of invasive MDA-MB-231 cells in immunodeficient mice. We speculated that there might be two reasons why miR-193b failed to downregulate the invasion and proliferation of metastatic MDA-MB-435 cells in vivo.
(1) MDA-MB-231 cells express high levels of endogenous uPA, whereas MDA-MB-435 cells contain a low level of uPA protein (Holst-Hansen et al., 1996) . To further confirm the conclusion, western blotting for uPA expression was performed to show that MDA-MB-231 cells express notably higher levels of uPA protein than do MDA-MB-435 cells (Supplementary Figure 2) . Therefore, the knockdown of uPA through miR-193b imposed an inefficient inhibitory effect on MDA-MB-435 xenografted tumors in nude mice. (2) uPA produced by host stromal cells promotes the growth and dissemination of xenograft tumors (Frandsen et al., 2001) . The two factors integrated might provide an explanation why miR-193b failed to disrupt the invasion and growth of MDA-MB-435 xenografted tumors in nude mice. The in vitro and in vivo 'rescue' experiments show that miR193b regulates the growth and invasion of breast cancer cells mainly by targeting uPA. Hence, uPA seems to be a major downstream effector of miR-193b in the miR193b target network. miR-193b was also shown as a negative regulator of uPA in breast cancerous tissues. Thus, the expression of miR-193b is downregulated in metastatic breast cancer by unknown mechanisms, which in turn upregulate uPA expression and contribute to the development of breast cancer. There have been findings which suggest that demethylation of the uPA promoter can be the mechanism responsible for induction of uPA expression in the initiation of early stages of breast cancer (Pakneshan et al., 2004a, b) . Here, we argue that the promoting effects of miRNA deregulation may be another crucial mechanism responsible for the induction of uPA expression in metastatic breast cancer. There are some disagreements about whether uPA expression correlates with lymph node metastasis (Foekens et al., 2000; Castello´et al., 2007) . There are other disagree- ments about whether uPA mRNA levels correlate with protein levels in breast cancer (Castello´et al., 2007; Biermann et al., 2008) . This might be caused by random sampling errors and difference in methods of data statistics. In our study, we showed a novel regulatory mechanism of the uPA gene expression in breast cancer. A recent report by Biermann et al. (2008) sustains our finding that uPA undergoes post-transcriptional regulation in breast cancer. miRNAs and their targets seem to form complex regulatory networks. Further study would be required to fully understand the role of each individual miRNA candidate in metastasis. In conclusion, our study defined a metastasis-associated pathway linking to miR-193b, in which loss of specific miRNA confers a selective advantage for cells destined for metastatic colonization. The strong association of the loss of miR-193b with metastasis suggests the potential for the use of miRNA molecules in prognostic stratification of breast cancer patients in addition to conventional clinical and pathological staging markers.
Materials and methods
Cell culture and human tissue samples Human breast cancer cell lines MDA-MB-231, MDA-MB-435, T47D, Hs578T and ZR-75-1 were grown in Dulbecco's minimal essential medium supplemented with 10% fetal bovine serum at 37 1C under 5% CO 2 . All frozen breast cancer primary tissues were obtained from the Department of Breast Surgery at Shanghai Cancer Hospital.
miRNA microarray and TaqMan real-time PCR Total RNA samples were sent to CapitalBio (CapitalBio Corp., Beijing, China) for miRNA microarray experiments. Procedures were performed as described in Guo et al. (2008) . microRNAs were isolated from the breast cancer cell lines as well as breast cancer tissues using the miRNeasy Mini Kit (Qiagen, Valencia, CA, USA), according to the manufacturer's protocol. The expression of mature microRNAs was assayed using TaqMan MicroRNA Assays (Applied Biosystems, Foster City, CA, USA) specific for hsa-miR-193b and RNU6B. Realtime PCR was performed using the TaqMan Gene Expression Master Mix (Applied Biosystems) and the ABI 7500 real-time There was a statistically significant Spearman's correlation that characterized an inverse relationship between miR-193b expression and uPA antigen expression (r ¼ À0.322; P ¼ 0.004). The ways of presenting the data and statistically analysing the data for every lane stem from the methods have been described earlier (Huang et al., 2008) . NS, not significant. PCR machine. RNU6B was used as an endogenous control. All TaqMan PCRs were performed in triplicates.
Construction of plasmids
For luciferase reporter experiments, the 3 0 UTR segment of the uPA gene was amplified by PCR using human cDNA as templates and inserted into the pGL3-control vector (Promega, Madison, WI, USA), using the XbaI site immediately downstream from the stop codon of luciferase (Volinia et al., 2006) . We also generated a mutant construct from the perfectly complementary site using the Quik Change Site-Directed Mutagenesis Kit (Stratagene, La Jolla, CA, USA). The coding sequence of human uPA was cloned into the pcDNA3.1(-) expression vector (Invitrogen, Carlsbad, CA, USA). Expression plasmids for hsa-miR-193b were created by PCR amplification using human genomic DNA as templates. The primers are as follows: (sense) 5 0 -CGGAATTCGCGACCCCCT GGCATTTTGGT-3 0 and (antisense) 5 0 -CGGGATCCCTTTCT CCTCCTTGTATCGTTTTTC-3 0 . The PCR products (510 bp containing the precursor and the flanking sequences) were cloned into the expression vector pCDH-CMV-MCS-EF1-Puro (System Biosciences, Mountain View, CA, USA). All constructs were confirmed by sequencing.
Luciferase activity assay
Transfection was performed in a 24-well plate using Lipofectamine 2000 (Invitrogen) in a final volume of 0.5 ml. For each well, cells were cotransfected using 400 ng of the firefly luciferase reporter vector, 1 ng of the control vector pRL-CMV (coding for Renilla luciferase, Promega) and 400 ng of the miR-193b expression vector or 40 nM miRNA inhibitor. Forty-eight hours after transfection, firefly and Renilla luciferase activities were measured using the Dual-Luciferase Reporter Assay system (Promega), and the relative reporter activity was normalized to the Renilla luciferase activity. Each assay was repeated in six independent experiments.
Western blotting
Equal amounts of protein were resolved by 12% SDSpolyacrylamide gel electrophoresis, and transblotted onto PVDF membrane (Millipore, Bedford, MA, USA). Then the membrane was incubated with specific antibody followed by horseradish peroxidase-linked immunoglobulin G, and visualized by chemiluminescence.
ELISA uPA antigen concentrations in cell culture supernatants were determined using the ELISA kit (American Diagnostica, Stamford, CT, USA) according to the manufacturer's instructions.
Real-time PCR for mRNA Real-time PCR was performed using a iCycler iQ5 Multicolor Real-Time PCR Detection System (BioRad, Hercules, CA, USA) with SYBR Green Supermix (TaKaRa, Tokyo, Japan). The cycling parameters are as follows: initial melting at 95 1C for 5 min, followed by 40 cycles of 95 1C for 15 s, 63 1C for 10 s and 72 1C for 20 s. Relative cDNA amounts were normalized to the expression of GAPDH.
In vitro migration and invasion assays For transwell migration assays, 5 Â 10 4 cells were plated into the top chamber with the non-coated membrane (24-well insert; pore size, 8 mm; BD Biosciences, Bedford, MA, USA). For transwell invasion assays, each well insert was layered with 80 ml of a 1:5 mixture of Matrigel/Dulbecco's minimal essential medium. A total of 10 Â 10 4 cells were added to the top of the Matrigel layer. In both assays, cells were plated in medium without serum, and NIH-3T3-conditioned medium was used as a chemoattractant in the lower chamber. The cells were incubated for 24 h, and cells that did not migrate or invade through the pores were removed by a cotton swab. Cells on the lower surface of the membrane were stained with Giemsa and counted.
In vitro proliferation experiment Cells were plated in 96-well plates at 2000 cells per well. Cell growth assays were performed using Cell Counting Kit-8 (CCK-8, Dojindo, Tokyo, Japan). At the indicated time points, 10 ml of the CCK-8 solution was added to the cells and incubated for 1 h at 37 1C and the absorbance was measured to calculate the number of vital cells in each well.
Immunohistochemical staining
Four-micrometer-thick histology sections from tumor specimens were cut, deparaffinized using xylene and hydrated through graded alcohol to water. Antigen retrieval was carried out by boiling at 100 1C for 10 min in 10 mM citrate buffer (pH 6.0). In brief, the sections were incubated in polyclonal antibody against human uPA (R & D Systems, Minneapolis, MN, USA) overnight at 4 1C. Subsequently, the horseradish peroxidase-conjugated antigoat secondary antibody (Dako Cytomation, Glostrup, Denmark) was applied and incubated for 1 h at room temperature. Detection was accomplished using 3,3 0 -diaminobenzidine reagent as the substrate. The extent of immunostaining was evaluated by the intensity of staining (score, 1-3) and staining density (score, 1-4). Intensity score was multiplied by the density score to calculate an overall score (1-12). Negative samples were scored '0'.
Animal model
The highly metastatic variant of parental MDA-MB-231 cells was obtained according to the method described earlier (Li et al., 2006) . For primary tumor growth assay and orthotopic metastasis assay, 3 Â 10 6 cells were injected into the MFP (mammary fat pad) of anesthetized athymic mice. Animals were monitored every 4 days for tumor growth and general health. The rate of primary tumor growth was determined by plotting the means of two orthogonal diameters of the tumors. The volume of tumor was calculated by the following formula: volume ¼ ab 2 /2, where a is the long diameter and b the short diameter. At the termination of the experiment, mice were killed and autopsied. The lung tissues were cut into 5-mm slices and every 10th section was stained with H&E to evaluate the presence or absence of lung metastasis. Two independent pathologists calculated the number of metastases in whole lungs. The xenograft tumors were collected for immunohistochemical evaluation of uPA antigen.
Statistical analysis
Data were analysed using Student's t-test or the two-tailed Mann-Whitney U-test. A P-value below 0.05 was considered statistically significant.
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